Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody that acts as an immunomodulator.Statement On A Nonproprietary Name Adopted By The USAN Council - Imgatuzumab, American Medical Association.

The drug was developed by Genentech/Roche.

References